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S U M M A R Y
Objectives: Cytomegalovirus (CMV) is a ubiquitous virus and its reactivation may lead to CMV end-organ
disease (CMV EOD) in immunocompromised patients and also in immunocompetent patients when they
are critically ill. We aimed to investigate the frequency and the clinical features of proven CMV EOD in
previously non-immunosuppressed patients admitted to our institution.
Methods: From January 2000 to March 2013, the records of all patients with a histopathological
diagnosis of CMV EOD at our teaching hospital were reviewed retrospectively. CMV EOD was diagnosed
histologically by the identiﬁcation of true cytomegalic viral inclusion involving endothelial, stromal,
and/or epithelial cells on hematoxylin and eosin staining, and was subsequently conﬁrmed by
immunohistochemistry using speciﬁc antibody against CMV antigens. Immunocompromised patients
were excluded.
Results: CMV EOD manifesting as colitis was diagnosed in 14 previously immunocompetent intensive
care unit (ICU) patients. The mean age of the patients was 64 years. All had co-morbidities and developed
shock before CMV EOD. The major manifestation was gastrointestinal bleeding. The in-hospital mortality
rate was 71.4% despite speciﬁc treatment with ganciclovir.
Conclusions: Despite being a rare condition, lower gastrointestinal bleeding in this proﬁle of ICU patients
could be the clinical manifestation of CMV colitis, and intensivists should be alert to this condition.
 2013 The Authors. Published by Elsevier Ltd on behalf of International Society for Infectious
Diseases. 
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Cytomegalovirus (CMV) is a ubiquitous virus and its serology is
positive in over two-thirds of the healthy population.1 Seropreva-
lence rates increase with age.2 Like other herpes viruses, CMV stays
in a dormant phase for the individual’s entire life.1–3 Therefore,
CMV reactivation may lead to CMV end-organ disease (CMV EOD)
in immunocompromised patients.2 The most frequently involved
organs are the retina, esophagus, lung, central nervous system, and
colon.3 Over the last decade, a few publications have reported CMV
EOD in previously immunocompetent patients, mostly during a
critical illness.3–6 However, the clinical relevance and prevalence
of CMV EOD in critically ill patients are not well understood. We* Corresponding author. Tel.: +55 11 2661 0000.
E-mail address: bruno_randi@yahoo.com.br (B.A. Randi).
1201-9712  2013 The Authors. Published by Elsevier Ltd on behalf of International S
http://dx.doi.org/10.1016/j.ijid.2013.11.008aimed to investigate the frequency and the clinical features of
proven CMV EOD in previously non-immunosuppressed patients
admitted to our institution.
2. Materials and methods
From January 2000 to March 2013, the records of all patients
with a histopathological diagnosis of CMV EOD at our teaching
hospital were reviewed retrospectively. The Heart Institute (InCor)
is a 500-bed tertiary care cardiology center in Sao Paulo, with 158
intensive care unit (ICU) beds. The SNOMED code and the terms
‘cytomegalovirus’ and ‘CMV’ were used to search for cases with a
histological diagnosis of CMV EOD in the electronic medical
records (biopsies and autopsies) of the pathology laboratory. CMV
EOD was diagnosed histologically by the identiﬁcation of true
cytomegalic viral inclusion on hematoxylin and eosin staining and
was subsequently conﬁrmed by immunohistochemistry using
speciﬁc antibody against CMV antigens (monoclonal mouse anti-
cytomegalovirus, clone DDG9 + CCH2/DAKO). Solid organ or
hematopoietic stem cell transplant recipients and patients withociety for Infectious Diseases. Open access under CC BY-NC-ND license.
Table 1
Clinical data of 14 previously non-immunosuppressed patients from admission to the ICU to biopsy-proven CMV EOD at a cardiology hospital
Case Patient
age
(years)/
sex
Comorbidities Diagnosis at
admission
Complications Septic
episodes
(n)
Hospital
length of
stay/ICU
(days)
MV/VA
(days)
Transfusion
of blood
components
(yes/ no)
CMV
clinical
manifestations
Diagnostic
resource
Site of
infection
In-hospital
outcome
1 80/M Hypertension +
cardiomyopathy
Pneumonia Septic + cardiogenic
shock
2 50/50 25/– No Hematochezia Colonoscopy Rectum Death
2 43/F Cardiomyopathy +
valvulopathy
CHF Cardiogenic shock – 23/0 –/– No Abdominal pain +
nausea + vomiting
Colonoscopy Cecum + left colon Death
3 82/F Pulmonary
hypertension +
cardiomyopathy
CHF Septic + cardiogenic
shock
1 35/13 7/6 Yes Diarrhea +
hematochezia
Colonoscopy Rectum Death
4 61/F DM +
cardiomyopathy
Elective myocardial
revascularization
Septic shock +
ventricular
ﬁbrillation
4 60/30 10/30 Yes Hematochezia Colonoscopy + left
hemicolectomy
Rectum + sigmoid Death
5 77/F DM,
cardiomyopathy +
Alzheimer’s disease
Myocardial infarct Septic + cardiogenic
shock
2 32/32 12/18 Yes Melena Colonoscopy Rectum + left colon Discharge
6 74/M Dialytic CRF +
cardiomyopathy +
valvulopathy +
hepatitis C
CHF Septic shock +
Clostridium colitis +
UTI
3 23/6 0/2 No Diarrhea Colonoscopy Terminal ileum Discharge
7 66/F DM + CRF +
cardiomyopathy
CHF Septic shock 3 48/34 0/34 Yes Melena +
hematochezia
Left hemicolectomy Left colon Death
8 38/F Chronic aortic
dissection
Surgical correction
of aortic dissection
Septic shock +
rhabdomyolysis +
acute renal injury +
surgical wound
infection + VAP
2 50/45 18/15 No Fever, diarrhea +
hematochezia
Colonoscopy +
autopsy
Left colon + sigmoid Death
9 47/M Hypertension + CRF
+ cardiomyopathy
Severe pneumonia Septic shock 3 38/37 35/20 Yes Diarrhea +
abdominal
distension +
vomiting
Colonoscopy +
autopsy
Cecum + left colon Death
10 71/F Cardiomyopathy +
CRF + COPD
CHF + myocardial
revascularization
Septic + cardiogenic
shock
2 50/39 39/39 Yes Melena Upper endoscopy Duodenum Death
11 53/M DM + previous
myocardial
revascularization
Myocardial
revascularization
Septic + cardiogenic
shock
2 35/15 5/2 Yes Fever +
hematochezia
Right
hemicolectomy
Right colon +
terminal ileum
Discharge
12 56/M Polyglandular
autoimmune
disease type II + CRF
Ischemic colitis Septic shock 1 41/13 0/0 No Diarrhea +
hematochezia
Colonoscopy + right
hemicolectomy
Right colon Death
13 73/F CRF + hypertension
+ DM +
cardiomyopathy
CHF Septic shock 2 97/82 42/30 Yes Melena +
hematochezia
Colonoscopy Left colon + sigmoid
+ rectum
Death
14 78/M CRF + hypertension Surgical correction
of aortic dissection
Septic shock 1 30/8 1/5 Yes Diarrhea Colonoscopy Sigmoid Discharge
CHF, congestive heart failure; CMV, cytomegalovirus; COPD, chronic obstructive pulmonary disease; CRF, chronic renal failure; DM, diabetes mellitus; EOD, end-organ disease; F, female; ICU, intensive care unit; M, male; MV,
mechanical ventilation; UTI, urinary tract infection; VA, vasopressin amines; VAP, ventilator-associated pneumonia.
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immunosuppressive drugs, chemotherapeutic agents, or cancer
treatment in the 6 months prior to the diagnosis of CMV EOD, were
excluded.
3. Results
We identiﬁed 14 patients who were previously considered non-
immunosuppressed and developed CMV EOD, all of them
presenting colitis. Patient characteristics are shown in Table 1.
The mean age of the patients was 64 years and all had co-
morbidities such as cardiomyopathy (64.2%), chronic kidney
disease (50%), and diabetes mellitus (35.7%). All developed septic
or cardiogenic shock before CMV EOD. At least one episode of
septic shock was seen in 13 patients (92.8%), with an average of
two episodes per patient. The mean in-hospital stay was 44 days,
with an average of 29 days in the ICU. In this series, 71.4% of
patients needed mechanical ventilation, with an average of 20 days
under ventilation. Eleven patients (78.5%) needed vasoactive drugs
(mean 19 days of use). The in-hospital mortality rate was 71.4%
despite speciﬁc treatment with ganciclovir. Only one patient
(number 8) did not receive speciﬁc treatment.
4. Discussion
Critically ill patients frequently demonstrate a transient
depression in immunity, predisposing them to viral reactivations,
like CMV.1,3 The detection of CMV in the blood in ICU patients leads
to increased mortality and morbidity in terms of increased ICU
stay, long-term mechanical ventilation, and higher rates of
nosocomial infection.1,2,7,8 A recent meta-analysis by Kalil and
Florescu showed that ICU patients with positive CMV serology at
admission, who stayed more than 5 days in the unit, or those who
had severe sepsis, were signiﬁcantly more prone to CMV EOD, with
a prevalence of 36%. They also had a higher mortality than patients
without CMV infection.1
CMV colitis in the immunocompetent host is an uncommon
disease and is rarely considered in the differential diagnosis in
patients who are not overtly immunocompromised.9 As well as the
patients described herein, CMV EOD has also been observed in
other critically ill ICU patients with a long hospital stay and
episodes of septic shock. A meta-analysis by Galiatsatos et al. found
44 cases of CMV colitis in immunocompetent patients over a 23-
year period. Fourteen patients (31.8%) died.3 In another study,
critically ill immunocompetent patients with CMV colitis had a
higher mortality rate and required a longer ICU stay.7
Similarly to our series, the major clinical manifestations of CMV
colitis in the literature are lower gastrointestinal bleeding andabdominal pain.6,8,9 Studies have shown a higher incidence of
transfusions in patients with active CMV during critical illness.3 In
our series, blood component transfusions were needed in 64.2%
due to bleeding related to CMV colitis. This suggests an aggressive
disease due to CMV reactivation and rules out CMV infection
related to blood transfusion.
There remains the dilemma of whether or not CMV viremia in
critically ill patients should be treated with ganciclovir.2 Although
there are no clinical studies on critically ill patients, these patients
would probably beneﬁt from early initiation of therapy.7,8
Histopathological evaluation of suspected patients should also
be performed in search of CMV colitis.8
This case series was restricted to patients with histological
evidence of CMV EOD and probably underestimates the prevalence
in this population. Most cases diagnosed as ‘probable’ CMV EOD
depend on diagnostic criteria that do not include histological
examinations.10
Despite being a rare condition – we found only 14 cases over 13
years of a retrospective search – lower gastrointestinal bleeding in
this proﬁle of ICU patients could be the clinical manifestation of
CMV colitis, and intensivists should be alert to this condition.
Conﬂict of interest: On behalf of all authors, the corresponding
author states that there is no conﬂict of interest.
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